A328130 Stock Overview
Provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Lunit Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩62,900.00 |
| 52 Week High | ₩85,800.00 |
| 52 Week Low | ₩31,000.00 |
| Beta | 1.45 |
| 1 Month Change | 14.57% |
| 3 Month Change | 43.28% |
| 1 Year Change | -23.67% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 214.50% |
Recent News & Updates
Shareholder Returns
| A328130 | KR Healthcare Services | KR Market | |
|---|---|---|---|
| 7D | -18.5% | -13.5% | -3.7% |
| 1Y | -23.7% | -33.5% | -10.4% |
Return vs Industry: A328130 exceeded the KR Healthcare Services industry which returned -33.5% over the past year.
Return vs Market: A328130 underperformed the KR Market which returned -10.4% over the past year.
Price Volatility
| A328130 volatility | |
|---|---|
| A328130 Average Weekly Movement | 14.7% |
| Healthcare Services Industry Average Movement | 11.1% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A328130's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A328130's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 345 | Beomseok Brandon Suh | www.lunit.io |
Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations.
Lunit Inc. Fundamentals Summary
| A328130 fundamental statistics | |
|---|---|
| Market cap | ₩1.82t |
| Earnings (TTM) | -₩21.97b |
| Revenue (TTM) | ₩39.54b |
46.0x
P/S Ratio-82.8x
P/E RatioIs A328130 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A328130 income statement (TTM) | |
|---|---|
| Revenue | ₩39.54b |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩39.54b |
| Other Expenses | ₩61.51b |
| Earnings | -₩21.97b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -759.22 |
| Gross Margin | 100.00% |
| Net Profit Margin | -55.58% |
| Debt/Equity Ratio | 21.6% |
How did A328130 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 21:20 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lunit Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jun Choi | Macquarie Research |
| Seun Young Park | Mirae Asset Securities Co., Ltd. |
| Jiwoo Baek | Shinhan Investment Corp. |